Potassium ion channels and human disease: phenotypes to drug targets?
A significant difficulty faced by the pharmaceutical industry is the initial identification and selection of macromolecular targets upon which de novo drug discovery programs can be initiated. A drug target should have several characteristics: known biological function; robust assay systems for in vitro characterization and high-throughput screening; and be specifically modified by and accessible to small molecular weight compounds in vivo. Ion channels have many of these attributes and can be viewed as suitable targets for small molecule drugs. Potassium (K+) ion channels form a large and diverse gene family responsible for critical functions in numerous cell types, tissues and organs. Recent discoveries, facilitated by genomics technologies combined with advanced biophysical characterization methods, have identified novel K+ channels that are involved in important physiologic processes, or mutated in human inherited disease. These findings, coupled with a rapidly growing body of information regarding modulatory channel subunits and high resolution channel structures, are providing the critical information necessary for validation of K+ channels as drug targets.
Curran
M E
ME
Axys Pharmaceuticals Inc. 11099 North Torrey Pines Road La Jolla CA 92037 USA. mark_curran@axyspharm.com.
D001709:Biotechnology; D015195:Drug Design; D004358:Drug Therapy; D006801:Humans; D015221:Potassium Channels / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D011487:Protein Conformation
D015221:Potassium Channels